# EDGAR Filing Document

**Accession Number:** 0002110603
**File Stem:** 0002110603-26-000002
**Filing Date:** 2026-2
**Character Count:** 5637
**Document Hash:** ca69b0dc7f99b3c21256eadb3d38be07
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0002110603-26-000002.hdr.sgml**: 20260212

**ACCESSION NUMBER**: 0002110603-26-000002

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 4

**CONFORMED PERIOD OF REPORT**: 20260204

**FILED AS OF DATE**: 20260212

**DATE AS OF CHANGE**: 20260212

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Cain Wettan Keeley M
- **CENTRAL INDEX KEY:** 0002110603

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-19731
- **FILM NUMBER:** 26628273

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DRIVE
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328

## Ex-24

![](poaforsection16filings001.jpg)

------

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Cain Wettan Keeley M<br><sub>(Last) (First) (Middle)</sub><br>333 LAKESIDE DRIVE<br><sub>(Street)</sub><br>FOSTER CITY, CA 94404<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>GILEAD SCIENCES, INC. [ GILD ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_EVP Gen Counsel,  Legal & Comp_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 3944 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 5440 | <sup>(2)</sup> | D |  |
| Restricted Stock Unit | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 11342 | <sup>(2)</sup> | D |  |
| Non-qualified Stock Option (Right to Buy) | <sup>(4)</sup> | 2032-03-10 | Common Stock | 3072 | $57.92 | D |  |
| Non-qualified Stock Option (Right to Buy) | <sup>(4)</sup> | 2033-03-10 | Common Stock | 4412 | $79.50 | D |  |
| Non-qualified Stock Option (Right to Buy) | <sup>(4)</sup> | 2034-03-10 | Common Stock | 6996 | $75.12 | D |  |
| Non-qualified Stock Option (Right to Buy) | <sup>(4)</sup> | 2035-03-10 | Common Stock | 5140 | $117.21 | D |  |

---

### Footnotes:

(1) The restricted stock units have a 4-year vesting schedule.  25% vest on the first anniversary of the grant date. The balance vest 6.25% quarterly thereafter until fully vested.

(2) Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.

(3) The restricted stock units have a three-year vesting schedule.  33.33% vest on each yearly anniversary of the date of grant until fully vested.

(4) The shares subject to the option have a four-year vesting schedule. 25% vest on the first anniversary of the date of grant. The balance vest 6.25% quarterly thereafter until fully vested.

**Signature:** /s/ Edward S. Son by Power of Attorney for Keeley M. Cain Wettan  
**Date:** 2026-02-12

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**